Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | HTR2C | P28335 | 6/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31737655 | 0.81 | HTR2C (0.53) | KDM4EGAAHTR2CHTTALDH1A1 | |
| Hydrochloric Acid SCHEMBL31737982 | 0.81 | HTR2C (0.49) | KDM4EGAAHTR2CHTTALDH1A1 | |
| SCHEMBL3889725 | 0.78 | HTR2C (0.47) | KDM4EGAAHTR2CHTTDRD2 | |
| SCHEMBL10667948 | 0.78 | KDM4E (0.64) | KDM4EGAAHTT | |
| Hydrochloric Acid SCHEMBL2799130 | 0.77 | HTR2C (0.46) | KDM4EGAAHTR2CHTTDRD2 | |
| SCHEMBL14782228 | 0.74 | RPS6KB1 (0.61) | — | |
| SCHEMBL30592058 | 0.73 | NEK2 (0.51) | KDM4EHTR2CHRH3ALDH1A1 | |
| SCHEMBL4987330 | 0.73 | NEK2 (0.51) | KDM4EHTR2CHRH3ALDH1A1 | |
| SCHEMBL19228214 | 0.73 | RPS6KB1 (0.53) | — | |
| SCHEMBL13956850 | 0.73 | FLT3 (0.55) | HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1673092-B1 | HETEROCYCLE-SUBSTITUTED PTERIDINE DERIVATIVES AND THEIR USE IN THERAPY | 4 AZA IP NV (BE) | 2007-08-15 | — | — | EP | disclosed |
| US-20070032477-A1 | Pteridine derivatives useful for making pharmaceutical compositions | 4 AZA BIOSCIENCE NV (BE) | 2007-02-08 | — | — | US | disclosed |
| EP-1673092-A1 | HETEROCYCLE-SUBSTITUTED PTERIDINE DERIVATIVES AND THEIR USE IN THERAPY | 4 AZA Bioscience nv (BE) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005039587-A1 | HETEROCYCLE-SUBSTITUTED PTERIDINE DERIVATIVES AND THEIR USE IN THERAPY | 4 AZA BIOSCIENCE NV (BE) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032477-A1 | Pteridine derivatives useful for making pharmaceutical compositions | TPMT, TYMS, TNF | KDM4E 2167/4885GAA 2543/4885HTR2C 3374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.